Cargando…

Nephrocalcinosis and retinal dystrophy, rare manifestations of MPV17-related mitochondrial depletion syndrome?()

Detalles Bibliográficos
Autores principales:	Finsterer, Josef, Zarrouk-Mahjoub, Sinda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024143/ https://www.ncbi.nlm.nih.gov/pubmed/27668186 http://dx.doi.org/10.1016/j.ymgmr.2016.09.002

Ejemplares similares

ND2 mutation with minimal coenzyme-Q responsive manifestations()
por: Finsterer, Josef, et al.
Publicado: (2017)

Clozapine for mitochondrial psychosis()
por: Finsterer, Josef, et al.
Publicado: (2017)

Impaired Hearing in Mitochondrial Disorders
por: Finsterer, Josef, et al.
Publicado: (2015)

Mitochondrial vasculopathy due to the m.3243A > G mutation is not restricted to the carotid artery
por: Finsterer, Josef, et al.
Publicado: (2016)

Mitochondrial myopathy, dysmorphism, exercise-induced vomiting and tachycardia the mutation m.4831G > A()
por: Finsterer, Josef, et al.
Publicado: (2017)

Arrhythmias in MELAS syndrome
por: Finsterer, Josef, et al.
Publicado: (2016)

MELAS syndrome due to the m.3291T > C mutation
por: Finsterer, Josef, et al.
Publicado: (2016)

Diagnosing Kearns-Sayre Syndrome Requires Genetic Confirmation
por: Finsterer, Josef, et al.
Publicado: (2016)

Diagnosis of Kearns-Sayre Syndrome Requires Comprehensive Work-up
por: Finsterer, Josef, et al.
Publicado: (2016)

Double trouble progressive external ophthalmoplegia and Huntington's disease()
por: Finsterer, Josef, et al.
Publicado: (2016)

Phenotypic heterogeneity of a compound heterozygous SUCLA2 mutation()()()
por: Finsterer, Josef, et al.
Publicado: (2016)

Phenotypic heterogeneity of MELAS()()
por: Finsterer, Josef, et al.
Publicado: (2016)

Low blood heteroplasmy-rate may cause late-onset MELAS()()()
por: Finsterer, Josef, et al.
Publicado: (2017)

Pathogenicity of the Homoplasmic m.8701A>G Variant Requires Confirmation
por: Finsterer, Josef, et al.
Publicado: (2016)

Onset of MELAS due to the m.3243A > G mutation is early if the large phenotypic variability is considered()()
por: Finsterer, Josef, et al.
Publicado: (2016)

Assessment of the phenotype genotype variability and correlation in m.3243A > G mutation carriers requires prospective studies
por: Finsterer, Josef, et al.
Publicado: (2016)

Unusual recovery of respiratory chain complex-III deficiency upon G-tube feeding and a cocktail
por: Finsterer, Josef, et al.
Publicado: (2016)

Detection of the mutation may guide treatment of heart and muscle in Duchenne muscular dystrophy
por: Finsterer, Josef, et al.
Publicado: (2016)

Mitochondrial multiorgan disorder syndrome score generated from definite mitochondrial disorders
por: Finsterer, Josef, et al.
Publicado: (2017)

Management of manifesting FOXRED1 carriers is complex
por: Finsterer, Josef, et al.
Publicado: (2019)

Costs for mitochondrial medicine will remain high as long as mitochondrial disorders are misdiagnosed()()()()
por: Finsterer, Josef, et al.
Publicado: (2017)

Biomarkers for Detecting Mitochondrial Disorders
por: Finsterer, Josef, et al.
Publicado: (2018)

Involvement of the Spinal Cord in Mitochondrial Disorders
por: Finsterer, Josef, et al.
Publicado: (2018)

MPV17-related hepatocerebral mitochondrial DNA depletion syndrome (MPV17-NNH) revisited
por: Qualls, Clifford, et al.
Publicado: (2016)

Mitochondrial multiorgan disorder syndrome (MIMODS) due to a compound heterozygous mutation in the ACAD9 gene()
por: Finsterer, Josef, et al.
Publicado: (2017)

Fibroblast growth-factor-21 is currently a weak biomarker for identifying mitochondrial and non-mitochondrial inborn errors of metabolism
por: Finsterer, Josef, et al.
Publicado: (2017)

Anti-mitochondrial M2 Antibodies and Myopathy
por: Finsterer, Josef, et al.
Publicado: (2017)

Letter to the Editor: Endocrine Compromise in Mitochondrial Disorders
por: Finsterer, Josef, et al.
Publicado: (2018)

Mitochondrial cardioencephalopathy due to a COQ4 mutation
por: Finsterer, Josef, et al.
Publicado: (2017)

Comment on “Role of Mitochondrial Genome Mutations in Pathogenesis of Carotid Atherosclerosis”
por: Finsterer, Josef, et al.
Publicado: (2018)

MicroRNAs are inappropriate for characterising hearing impairment in mitochondrial disorders
por: Finsterer, Josef, et al.
Publicado: (2018)

Treating mitochondrial disorders requires full exploitation of available therapeutic options
por: Finsterer, Josef, et al.
Publicado: (2017)

Suspicion of mitochondrial disease remains frequently unconfirmed after whole exome sequencing
por: Finsterer, Josef, et al.
Publicado: (2018)

Comment on “A Rare Case of Renal Infarct due to Noncompaction Cardiomyopathy: A Case Report and Literature Review”
por: Finsterer, Josef, et al.
Publicado: (2016)

Comment to: Focal segmental glomerulosclerosis associated with mitochondrial disease by Lim et al. in Clin Nephrol Case Stud. 2017; 5: 20-25.
por: Finsterer, Josef, et al.
Publicado: (2018)

Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) due to a m.10158T>C ND3 Mutation with a Normal Muscle Biopsy
por: Finsterer, Josef, et al.
Publicado: (2017)

Fatigue and Exercise Intolerance as Initial Manifestations of a Nonsyndromic Mitochondrial Disorder Due to the Variant m.3243A>G
por: Finsterer, Josef, et al.
Publicado: (2022)

Why does Leigh syndrome respond to immunotherapy?
por: Finsterer, Josef, et al.
Publicado: (2016)

Diagnose Kearns–Sayre syndrome genetically and investigate the phenotype comprehensively
por: Finsterer, Josef, et al.
Publicado: (2016)

Vaccination triggering onset of m.8993T > G associated Leigh syndrome
por: Finsterer, Josef, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gubos4lrjf51itia70vta7f1qt